Latest News and Press Releases

Saint-Herblain (France), December 20, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs,...

Saint-Herblain (France), December 12, 2019 – Valneva SE (“Valneva” or “the Company”) today announced the appointment of MVM Partner Thomas Casdagli to its Supervisory Board. Mr. Casdagli is replacing...

Saint-Herblain (France), 12 décembre 2019 – Valneva SE (“Valneva” ou “le Groupe”) annonce aujourd’hui la nomination de Thomas Casdagli, Associé de la société MVM Partners LLP, à son Conseil de...

Saint-Herblain (France), 9 décembre 2019 – Valneva SE (“Valneva” ou “le Groupe”) a annoncé aujourd’hui la nomination de deux experts des vaccins de renommée mondiale à son Conseil Scientifique (SAB)....

Saint-Herblain (France), December 9, 2019 – Valneva SE (“Valneva” or “the Company”) today announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Dr. Stanley...

Saint-Herblain (France), December 5, 2019 – Valneva SE (“Valneva”), announced today that its management team including Thomas Lingelbach, CEO, David Lawrence, CFO, and Franck Grimaud, CBO, will hold...

Saint-Herblain (France), 5 décembre 2019 – Valneva SE (“Valneva”) a annoncé aujourd’hui que son équipe dirigeante, dont Thomas Lingelbach, CEO, David Lawrence, CFO et Franck Grimaud, CBO, rencontrera...

Saint Herblain (France), 28 novembre 2019 – Valneva SE (“Valneva” ou “le Groupe”), a annoncé aujourd’hui que l’agence européenne du médicament (EMA) a approuvé une prolongation de la durée...

Saint Herblain (France), November 28, 2019 – Valneva SE (“Valneva” or “the Company”), today announced that the European Medicines Agency (EMA) has approved the extension of the shelf life of its...

Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans Final Phase 1 results up to Month 13 confirm the excellent immunogenicity and safety profile for...